EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Marijuana Use for Symptom Control in Inflammatory Bowel Disease: Patients’ Perceptions and Patterns of Use

Arvin Daneshmand, Karen Yung, Hanzhi Gao, Chelsea Salmon, Nofel Iftikhar, Saroja Devi Rampertab, Angela Kim Pham, Ludmila De Faria, Ellen Mary Zimmermann, Naueen A Chaudhry

Medical Cannabis and Cannabinoids · 07.07.2026 · 9 (1) · 211-223

DOI: 10.1159/000553354 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Cannabis and Cannabinoids, online erschienen am 07.07.2026. Verfasst von Arvin Daneshmand und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, University of Florida, Gainesville, FL, USA. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Many patients with inflammatory bowel disease (IBD) use marijuana for disease-related symptoms. Data regarding reasons for usage, impact, and perceptions on its effects is lacking. Our study aimed to understand patterns of marijuana use, underlying symptom response, and beliefs about marijuana in patients with IBD.

Methods

An anonymous REDCap survey comprised of 39 questions on demographics, disease features, patterns of marijuana use, symptoms, quality of life, and true/false statements about marijuana was administered to 108 participants recruited from University of Florida (UF) IBD clinic.

Results

Participants were 47.2% male and 51.9% female. While a significant percentage of subjects reported co-morbid depression/anxiety (61.1%), the percentages for PTSD and ADHD are both 19.4%. Patient characteristics are compared among three reasons of marijuana use (Recreational, Medical and Combination). There was a notable shift in reasons for use with both age (p = 0.0074) and duration of IBD diagnosis (p = 0.006): recreational use is more common among younger patients and those with a shorter duration of IBD diagnosis, medical use becomes predominant in middle-aged patients and those with an intermediate duration of diagnosis, and combination use increases among older patients and those with the longest duration of IBD diagnosis. Comparisons are also conducted based on the frequency of marijuana usage. Associations were found between marijuana use frequency and symptom relief. Daily or near-daily marijuana use was associated with self-reported relief of nausea/vomiting (82.1%; p = 0.003), arthralgias (81%; p = 0.013), and insomnia (80%; p = 0.02). Additionally, marijuana use was linked to an improved ability to live independently (p = 0.0075) and current employment (p = 0.04). Patients with a history of bowel surgery were more likely to report marijuana use lasting longer than 5 years (OR 21.94, CI [2.91, 250.18], p = 0.0059) and using marijuana at least once weekly (OR 11.13, CI [1.78, 97.69], p = 0.0163). Notably, 59.3% of respondents believed marijuana use had reduced their opioid consumption. Marijuana users with a history of IBD-related hospitalization had higher odds of reporting depression/anxiety (OR 14.3, CI [2.34, 143.2], p = 0.009) and diarrhea symptoms (OR 13.3, CI [2.2, 128.9], p = 0.01). When asked how marijuana use affected their ability to live independently, 61.3% of participants reported “improved.” Similarly, 87.6% respondents reported improvement in their quality of life with marijuana use.

Conclusions

Marijuana can be helpful for symptom control, reducing reliance on opioid pharmaceuticals, and may improve quality of life in patients with IBD. Participants demonstrated good insight regarding the role of marijuana in the management of their disease.

Schlagwörter

Stichwörter der Autor:innen

AnxietyCrohn’s diseaseInflammatory bowel diseaseMarijuanaOpioid use disorderQuality of lifeUlcerative colitis

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, University of Florida, Gainesville, FL, USA.
  • Department of Biostatistics, University of Florida, Gainesville, FL, USA.
  • Department of Psychiatry, University of Florida, Gainesville, FL, USA.

Zitieren

APA

Daneshmand, A., Yung, K., Gao, H., Salmon, C., Iftikhar, N., Rampertab, S. D., Pham, A. K., De Faria, L., Zimmermann, E. M., & Chaudhry, N. A. (2026). Marijuana Use for Symptom Control in Inflammatory Bowel Disease: Patients’ Perceptions and Patterns of Use. Medical Cannabis and Cannabinoids, 9(1), 211-223. https://doi.org/10.1159/000553354

Vancouver

Daneshmand A, Yung K, Gao H, Salmon C, Iftikhar N, Rampertab SD, et al. Marijuana Use for Symptom Control in Inflammatory Bowel Disease: Patients’ Perceptions and Patterns of Use. Medical Cannabis and Cannabinoids. 2026;9(1):211-223. doi:10.1159/000553354

BibTeX
@article{Daneshmand2026,
  author = {Daneshmand, Arvin and Yung, Karen and Gao, Hanzhi and Salmon, Chelsea and Iftikhar, Nofel and Rampertab, Saroja Devi and Pham, Angela Kim and De Faria, Ludmila and Zimmermann, Ellen Mary and Chaudhry, Naueen A},
  title = {Marijuana Use for Symptom Control in Inflammatory Bowel Disease: Patients’ Perceptions and Patterns of Use},
  journal = {Medical Cannabis and Cannabinoids},
  year = {2026},
  volume = {9},
  number = {1},
  pages = {211--223},
  doi = {10.1159/000553354}
}
Kostenlos starten →